TABLE 2.
Clinical and phenotypic characteristics of patients with PD‐L1+ IVLBCL and PD‐L1+ eDLBCL
| Variables | PD‐L1+ IVLBCL (n = 12) | PD‐L1+ eDLBCL (n = 7) | P |
|---|---|---|---|
| Sex (male/female) | 5/7 | 4/3 | .65 |
| Age, median (range) | 74 (51‐81) | 72 (59‐84) | .68 |
| Age > 60 y | 9/12 (75%) | 6/7 (86%) | 1.0 |
| Performance status > 1 | 8/12 (75%) | 6/7 (86%) | .60 |
| IPI (HI/H) | 10/11 (91%) | 5/7 (71%) | .53 |
| Stage III/IV | 11/12 (92%) | 4/7 (57%) | .12 |
| plt < 14 × 104/μL | 9/11 (82%) | 5/6 (83%) | 1.0 |
| WBC < 3.5 × 103/μL | 4/11 (36%) | 3/7 (43%) | 1.0 |
| Alb < 3.0 g/dL | 8/11 (73%) | 3/6 (50%) | .59 |
| CRP > 1.0 mg/dL | 11/11 (100%) | 3/5 (60%) | .083 |
| sIL‐2R > normal | 11/12 (92%) | 7/7 (100%) | 1.0 |
| LDH > normal | 11/11 (100%) | 6/7 (94%) | .39 |
| B symptoms | 8/12 (67%) | 5/7 (71%) | 1.0 |
| Hepatomegaly | 2/12 (8.3%) | 1/7 (14%) | 1.0 |
| Splenomegaly | 7/12 (58%) | 2/7 (29%) | .35 |
| CD5 positivity | 2/7 (29%) | 2/7 (29%) | 1.0 |
| COO (GCB/non‐GCB subtype) | 1/6 | 0/7 | 1.0 |
Abbreviations: Alb, albumin; CNS, central nervous system; COO, cell of origin; CRP, C‐reactive protein; GCB, germinal center B cell; H, high; Hb, hemoglobin; HI, high‐intermediate; HPS, hemophagocytic syndrome; IPI, international prognostic index; LDH, lactate dehydrogenase; plt, platelet; sIL‐2R, soluble interleukin‐2 receptor; WBC, white blood cell.